{"name":"PAVmed","slug":"pavmed","ticker":"PAVM","exchange":"NASDAQ","domain":"pavmed.com","description":"PAVmed Inc. engages in acquiring, developing, and commercializing novel products that target unmet needs in the United States. The company's lead products include CarpX, a patented, single-use, disposable, and minimally invasive surgical device for use in the treatment of carpal tunnel syndrome; EsoCheck Esophageal Cell Collection Device, which consists of diagnostic test that serves as a testing tool for preventing esophageal adenocarcinoma deaths, through early detection of esophageal precancer in at-risk gastroesophageal reflux disease, including chronic heartburn and acid reflux or simply reflux in patients; and EsoGuard, a bisulfite-converted next-generation sequencing DNA assay performed on surface esophageal cells collected with EsoCheck device. Its product pipeline also comprises EsoCure Esophageal Ablation Device for treating dysplastic BE; PortIO, an implantable intraosseous vascular access device; and Veris cancer care platform. The company was formerly known as PAXmed Inc. ","hq":"New York, NY","founded":0,"employees":"41","ceo":"Lishan Aklog","sector":"Medical Technology / Diagnostics","stockPrice":6.45,"stockChange":0.14,"stockChangePercent":2.22,"marketCap":"$47M","metrics":{"revenue":3000000,"revenueGrowth":420,"grossMargin":-207,"rdSpend":4492000,"netIncome":401000,"cash":1952000,"dividendYield":0,"peRatio":-2.4,"fiscalYear":"FY2024"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2024-02-28","type":"earnings","headline":"PAVmed Reports Fourth Quarter and Full Year 2023 Financial Results","summary":"PAVmed reported its financial results for the fourth quarter and full year 2023, with revenue of $1.3 million and a net loss of $13.4 million.","drugName":"","sentiment":"neutral"},{"date":"2023-11-15","type":"deal","headline":"PAVmed Announces Collaboration with University of California, San Francisco (UCSF) to Develop Novel Diagnostic Test for Esophageal Cancer","summary":"PAVmed has partnered with UCSF to develop a new diagnostic test for esophageal cancer, leveraging the company's EsoGuard technology.","drugName":"","sentiment":"positive"},{"date":"2023-08-01","type":"regulatory","headline":"PAVmed Receives FDA 510(k) Clearance for PortPAC System","summary":"PAVmed has received FDA clearance for its PortPAC system, a minimally invasive device for treating varicose veins.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiqAFBVV95cUxOY1JoaENFamlWMEFHU1FONDRfdGVEOWFMbVduNm40VzQ1MjFxTjRsUk9CaWZ3Rk1zWnFsMUx4WnA3Z3FYNmM1LWRybURTcWpOWGJEMlQtX0hydnZsZjJHUlVuUkZoX1hVR3RnRkt4anNlbXNXOHBWczl3WnRNYndxZ082MGxYZ2lMb2tkdlVZT1J2Z2ZtQ2ZaMlNxaGk2TkRHOEZiaHZlemU?oc=5","date":"2026-04-03","type":"pipeline","source":"Stock Titan","summary":"PAVmed (PAVM) director Timothy Baxter receives 13,930 restricted shares vesting in 2029 - Stock Titan","headline":"PAVmed (PAVM) director Timothy Baxter receives 13,930 restricted shares vesting in 2029","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqAFBVV95cUxPb0NVT3FjaXFDdTJzLVRwcDdlZDNNTGtaT21JeWpfNWlEOGY1MjloXzRuTTFib1VUNHpHUzl4U28xV0ZBbV9qNlFBZzlldDR6SUJ1OC1WVFFPcFl2eGZ3aEttZThXZmtrQzM5LVJERXZnYklQekNfQmdzdFFvbXNHZmx4N0ZxZjhYT2t6YWdZWEtkSFc5Xy1GNGRnNkdwaDFub3NJY200TWE?oc=5","date":"2026-04-03","type":"pipeline","source":"Stock Titan","summary":"PAVmed (PAVM) CEO Lishan Aklog awarded 350,000 restricted shares vesting 2029 - Stock Titan","headline":"PAVmed (PAVM) CEO Lishan Aklog awarded 350,000 restricted shares vesting 2029","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqAFBVV95cUxQa1BYUzJDSnFjX0IxRk1MS3BJNkJ6MUdlVHFRU0VZcWRaX1VnZk9XZ3YwbGpHWDJEQWNMdE5kS0JibExrYnhPYlhnMVgtdlQtVGhoWnR4THliY1d2cV9sMnRwVDROWlJrTmRGaXdnM19Rb1d6WnJSbjh6ajJDM3BnelVPVDlIZnl1aFR4TTBBSEYwOGkwdGxLeHN3cGZSUXVLMnpvRVBCQXA?oc=5","date":"2026-04-03","type":"pipeline","source":"Stock Titan","summary":"PAVmed (PAVM) CFO awarded 180,000 restricted shares vesting 2029 - Stock Titan","headline":"PAVmed (PAVM) CFO awarded 180,000 restricted shares vesting 2029","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqAFBVV95cUxQU1o4UTV4U2tuOWF2VEVSeEkxbkJ0Q2tncEEzYTVjc0Nnem9rZ0pFNjVQWFRDY2t4a3hZOE9UNGIxOGY2cDB2TXdZNVQxYWFFdW1GaTl4ckxzMFRBanBYZ05FdHB5OGhoN1pMMGRuQ3NzVlNoYXdURG1WeXJUZWtMZnNBQlVucVltVm51c3hlb1pYRGt3ajJPdmZxRWlrb2M2WURZYm5BMm8?oc=5","date":"2026-04-03","type":"pipeline","source":"Stock Titan","summary":"PAVmed (PAVM) director gets 13,930-share restricted stock grant - Stock Titan","headline":"PAVmed (PAVM) director gets 13,930-share restricted stock grant","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqAFBVV95cUxQUXk4dExSUXp2Q2NlTmRlQnpQdW05eExMcjNPMk51NXlXY094T2dPcHdvZkpMLXpVZnFPNndDSk13OTVPYlJOUG5SeFUwWEJiNFl3Vkg0R3RWMmEtbkpSNE9BMzJaeFlOSllWWFNJdHJlQWtiRk1uSlV6bGxjdTVVU0hKTXhIVnN2R0dTWTJxX2JBOXZMUGh5YXpBWk1xUGlwZkEybDN1VlM?oc=5","date":"2026-04-03","type":"pipeline","source":"Stock Titan","summary":"Restricted stock grant boosts PAVmed (PAVM) director’s holdings - Stock Titan","headline":"Restricted stock grant boosts PAVmed (PAVM) director’s holdings","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiugFBVV95cUxNdFRuem0tWUNoUVVLTHA5UU9PYVV0eXpIZGpRekI5S1RWVS1IV1NyM2FFYVV3Q1pyU21qS0FuaXVMdFNXa2pUWHZnZTl1cEhhNEQ2WXVWN0MwNFBfbks1aW40bjRDak5tQ3plQ3Y2RVRvMnd3OVVSMWwxdWVRWjczTERxczhmMTJwenBmRXNobUtUZi1mYVNna0RVT01wWUpuRDk1WE1OZUFxZ05oeUtseGY2aTN6M1NVU1E?oc=5","date":"2026-04-03","type":"pipeline","source":"Stock Titan","summary":"Craig Kallman (PAVM) holds 384,616 shares, a 6.0% stake in PAVmed - Stock Titan","headline":"Craig Kallman (PAVM) holds 384,616 shares, a 6.0% stake in PAVmed","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirgFBVV95cUxNN1EybUoydzZhR0k1Z3pndGNCVU1Nay1ab0ZlUGhwelFIaTJfRFlWQVZOQVlmeGgyQ2ViVkJSWGtTOUF1NFlmbFdWR3cwN3hqbDE0ei1WSTZPSmNOV0ItWVdVRGVvTnVSM1M5UFZzOEl0QjFVWG5vcGFiSE9ZVjMwVFpHeDNwLWFIRzY1dUY0cTVSVW8wb0hKNUFGRlBBRFhBa0lYbjVITzlncG82SWc?oc=5","date":"2026-03-31","type":"deal","source":"MSN","summary":"PAVmed (PAVM) upgraded to buy: Here's what you should know - MSN","headline":"PAVmed (PAVM) upgraded to buy: Here's what you should know","sentiment":"neutral"},{"date":"2026-03-30","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2026-03-27","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2026-03-27","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: FORM 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijwFBVV95cUxOVGkyQno5anU4TkRPQW03WWdXT1UtaWcxX3NGdnFVZlFINHE3clRtb3hpTFlxQVhxd1ZzNVd2bWNoY1NXblNQNTlCMXRRVkp4azh3TlkxV2Znb1BNWEw1Qm1fMHhnQ05RVXlXQTJYX01VendtNVZPc2FwUlIzbGExckJjbHhjNmM3cDJVUUYxdw?oc=5","date":"2026-01-21","type":"pipeline","source":"Seeking Alpha","summary":"PAVmed-subsidiary Lucid Diagnostics spikes on Veterans Affairs contract - Seeking Alpha","headline":"PAVmed-subsidiary Lucid Diagnostics spikes on Veterans Affairs contract","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilwFBVV95cUxNdWFwWWZQRUtOUndpYUpMZzh6anJlOUxJUGtLdHVHRjhCZVJLaFNfN3k5SDJReDNfOUlsNjdMV0hoYmZlN3BKYWhranhCWDVFQ2xhbzJPdEJ6OGZwdXh3ckE3TndfYlBkSzVUM2NaWDhQbnA3RUVaSlU3SEtPSHZwZk5zUjYyQm1HRkowdnhva0hjR0JacHRn?oc=5","date":"2025-12-30","type":"pipeline","source":"PR Newswire","summary":"PAVmed Announces Reverse Stock Split - PR Newswire","headline":"PAVmed Announces Reverse Stock Split","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiaEFVX3lxTE1jc01GWmhDMWZwZ1JFSXprLVMxcUd3a2t1OE01UzBVYUc0UzlnakNEb2lHb2x0XzQ0N29LUXhOVUxfWnlzdmQxbkJIbFJ6MHVfc0hSTG5jU1NSOGtUcFczTFI1S3VsZmI2?oc=5","date":"2025-07-10","type":"regulatory","source":"MarketBeat","summary":"PAVmed (PAVM) FDA Approvals, PDUFA Dates & Drug Alerts 2026 - MarketBeat","headline":"PAVmed (PAVM) FDA Approvals, PDUFA Dates & Drug Alerts 2026","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiSEFVX3lxTE0wWDJIdk9sQjVId3VQM1hOVEo4Tlg3ZmRtb2VTeE1KaE51LWx5SVh1X3RiRkZpZ2U4eXVXSXB2QXNKb05leElRZg?oc=5","date":"2025-03-26","type":"pipeline","source":"Intellectia AI","summary":"PAVM Stock: Price, Forecast, Financials & AI Analysis - Intellectia AI","headline":"PAVM Stock: Price, Forecast, Financials & AI Analysis","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiTkFVX3lxTE9PTVpfWEk3Wmo0Q0xjTGFqNi0wQm0wZkJHRm9UV1BYcEtScGNZU01CaEtrRlNEU1dkQWZRenNRQVZWdWdSSmwwT1dfSU1CUQ?oc=5","date":"2020-09-12","type":"pipeline","source":"Stock Titan","summary":"Latest PAVM News - PAVmed Appoints Joseph Virgilio to Lead Rel... - Stock Titan","headline":"Latest PAVM News - PAVmed Appoints Joseph Virgilio to Lead Rel...","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Boston Scientific","Medtronic","Becton Dickinson"],"therapeuticFocus":["Cardiovascular","Gastrointestinal"],"financials":{"source":"sec_edgar+yahoo","revenue":3000000,"revenuePeriod":"2024-12-31","revenueHistory":[{"value":3000000,"period":"2024-12-31"},{"value":2500000,"period":"2023-12-31"}],"grossProfit":-147000,"grossProfitHistory":[{"period":"2025-12-31","value":-147000},{"period":"2024-12-31","value":-1845000},{"period":"2023-12-31","value":-3968000},{"period":"2022-12-31","value":-3237000}],"rdSpend":4492000,"rdSpendHistory":[{"period":"2025-12-31","value":4492000},{"period":"2024-12-31","value":5932000},{"period":"2023-12-31","value":14276000},{"period":"2022-12-31","value":25338000}],"sgaSpend":17167000,"operatingIncome":-21390000,"operatingIncomeHistory":[{"period":"2025-12-31","value":-21390000},{"period":"2024-12-31","value":-44378000},{"period":"2023-12-31","value":-68795000},{"period":"2022-12-31","value":-91087000}],"netIncome":401000,"netIncomeHistory":[{"period":"2025-12-31","value":401000},{"period":"2024-12-31","value":39791000},{"period":"2023-12-31","value":-64175000},{"period":"2022-12-31","value":-88983000}],"eps":-5.63001,"epsHistory":[{"period":"2025-12-31","value":-5.63001},{"period":"2024-12-31","value":15},{"period":"2023-12-31","value":-274.8},{"period":"2022-12-31","value":-450.9}],"cash":1538000,"cashHistory":[{"period":"2025-12-31","value":1538000},{"period":"2024-12-31","value":1185000},{"period":"2023-12-31","value":19639000},{"period":"2022-12-31","value":39744000}],"totalAssets":38812000,"totalLiabilities":16512000,"totalDebt":13348000,"equity":33967000,"operatingCashflow":-5206000,"operatingCashflowHistory":[{"period":"2025-12-31","value":-5206000},{"period":"2024-12-31","value":-33554000},{"period":"2023-12-31","value":-52036000},{"period":"2022-12-31","value":-70985000}],"capex":-31000,"capexHistory":[{"period":"2025-12-31","value":-31000},{"period":"2024-12-31","value":-55000},{"period":"2023-12-31","value":-242000},{"period":"2022-12-31","value":-1540000}],"freeCashflow":-5237000,"dividendsPaid":null,"buybacks":0,"employees":41,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[{"sga":4942000,"ebit":-2752000,"ebitda":-2734000,"period":"2025-12-31","revenue":52000,"epsBasic":-2.355774,"netIncome":-1263000,"rdExpense":1828000,"epsDiluted":-61.5,"grossProfit":-33000,"operatingIncome":-6648000},{"sga":3706000,"ebit":-6003000,"ebitda":-5981000,"period":"2025-09-30","revenue":5000,"epsBasic":-8.7,"netIncome":-5383000,"rdExpense":1088000,"epsDiluted":-8.7,"grossProfit":-50000,"operatingIncome":-4681000},{"sga":3890000,"ebit":-12320000,"ebitda":-12298000,"period":"2025-06-30","revenue":6000,"epsBasic":-22.2,"netIncome":-11921000,"rdExpense":790000,"epsDiluted":-22.2,"grossProfit":-35000,"operatingIncome":-4635000},{"sga":4631000,"ebit":18627000,"ebitda":18670000,"period":"2025-03-31","revenue":8000,"epsBasic":38.4,"netIncome":18968000,"rdExpense":787000,"epsDiluted":10.2,"grossProfit":-28000,"operatingIncome":-5428000},{"sga":4342000,"ebit":1149000,"ebitda":1218000,"period":"2024-12-31","revenue":10000,"epsBasic":3.286909,"netIncome":1431000,"rdExpense":807000,"epsDiluted":3.286909,"grossProfit":-38000,"operatingIncome":-5078000},{"sga":null,"ebit":null,"ebitda":null,"period":"2024-09-30","revenue":null,"epsBasic":null,"netIncome":null,"rdExpense":null,"epsDiluted":null,"grossProfit":null,"operatingIncome":null}]},"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":6.45,"previousClose":6.31,"fiftyTwoWeekHigh":28.44,"fiftyTwoWeekLow":6,"fiftyTwoWeekRange":"6.0 - 28.44","fiftyDayAverage":9.22,"twoHundredDayAverage":10.92,"beta":0.64,"enterpriseValue":64256860,"forwardPE":-2.4,"priceToBook":0.64,"priceToSales":660.69,"enterpriseToRevenue":905.03,"enterpriseToEbitda":-2.96,"pegRatio":0,"ebitda":-21701000,"ebitdaMargin":0,"freeCashflow":-13997875,"operatingCashflow":-5206000,"totalDebt":13348000,"debtToEquity":59.9,"currentRatio":0.17,"returnOnAssets":-39.2,"returnOnEquity":-32.3,"analystRating":"","recommendationKey":"none","numberOfAnalysts":2,"targetMeanPrice":40.5,"targetHighPrice":65,"targetLowPrice":16,"dividendRate":0,"payoutRatio":0,"fiveYearAvgDividendYield":0,"exDividendDate":0,"insiderHeldPercent":42.7,"institutionHeldPercent":10,"sharesOutstanding":7272739,"floatShares":1696366,"sharesShort":17722,"shortRatio":1.27,"shortPercentOfFloat":0.2,"epsTrailing":-5.63,"epsForward":-2.74,"revenuePerShare":0.11,"bookValue":10.01,"officers":[{"age":59,"name":"Dr. Lishan  Aklog M.D.","title":"Chairman & CEO"},{"age":43,"name":"Mr. Shaun M. O'Neill M.B.A.","title":"Executive VP & COO"},{"age":50,"name":"Mr. Michael Adam Gordon","title":"Executive VP, General Counsel & Secretary"},{"age":60,"name":"Dr. Brian J. deGuzman M.D.","title":"Executive VP, Chief Technology & Compliance Officer"},{"age":null,"name":"Dr. Suman M. Verma M.D., Ph.D.","title":"Senior VP of Molecular Genetics & Chief Scientific Officer"},{"age":null,"name":"Mr. Matthew  Riley","title":"Senior Director of Investor Relations"},{"age":null,"name":"Dr. Deepika A. Lakhani Ph.D.","title":"Senior VP, Chief Regulatory & Quality Officer"},{"age":39,"name":"Dr. Victoria T. Lee M.D.","title":"Executive Vice President & Chief Medical Officer"}],"industry":"Medical Devices","irWebsite":"","website":"https://www.pavmed.com","phone":"917 813 1828"}}